Advertisement

Topics

Latest "ProCyte Corporation" News Stories

07:52 EST 18th December 2018 | BioPortfolio

Here are the most relevant search results for "ProCyte Corporation" found in our extensive news archives from over 250 global news sources.

More Information about ProCyte Corporation on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about ProCyte Corporation for you to read. Along with our medical data and news we also list ProCyte Corporation Clinical Trials, which are updated daily. BioPortfolio also has a large database of ProCyte Corporation Companies for you to search.

Showing "ProCyte Corporation" News Articles 1–25 of 601

Tuesday 18th December 2018

Herantis Pharma Plc's financial reporting schedule and annual general meeting in 2019

Herantis Pharma Plc's financial reporting schedule and annual general meeting in 2019 Herantis Pharma Plc. Company release 18 December 2018 at 9:00 am Herantis Pharma Plc ("Herantis") will publish its Financial Statements in regard to 2018 on the 28th of February 2019. The financial reporting schedule of Herantis in 2019 is as follows: Financial Statements bulletin in ...


Idorsia's P2Y12 receptor antagonist - selatogrel - Phase 2 clinical studies meet their objective

Idorsia Pharmaceuticals Ltd. / Idorsia's P2Y12 receptor antagonist - selatogrel - Phase 2 clinical studies meet their objective . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland - December 18, 2018Idorsia Ltd (SIX: IDIA) today announced that Phase 2 clinical studies with selatogrel (...

Monday 17th December 2018

Galapagos reports initiation of ISABELA Phase 3 program with GLPG1690 in patients with Idiopathic Pulmonary Fibrosis (IPF)

Mechelen, Belgium; 17 December 2018, 22.15 CET - Galapagos NV (Euronext & NASDAQ: GLPG) today announces that it has dosed its first patient in the worldwide ISABELA Phase 3 program with autotaxin inhibitor GLPG1690 in IPF. "Today's news again demonstrates our commitment to the rapid advancement of our IPF franchise, including the ISABELA and the PINTA trials. We are excited b...


FDA Approves Smart Programmer for the InterStim System

Intuitive and Discreet Device Provides Sacral Neuromodulation Therapy for Overactive Bladder and Bowel Incontinence DUBLIN - December 17, 2018 - Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval of the InterStim(TM) smart programmer for use with the InterStim system, which provides sacral neuromodulation therapy for the treatment of overactive...

Acarix reports first patient enrollment in new clinical investigation exploring heart failure detection

Press release Malmö, Sweden December 17, 2018 Acarix reports first patient enrollment in new clinical investigation exploring heart failure detection Acarix has initiated a new explorative clinical study to develop a diagnostic algorithm possibly leading to a new functionality for early detection of heart failure using the CADScor®System. In the investigation, titled "Identification...

GENFIT: Positive 30-month DSMB Recommendation for Continuation of Phase 3 RESOLVE-IT Study of Elafibranor in NASH

GENFIT: Positive 30-month DSMB Recommendation for Continuation of Phase 3 RESOLVE-IT Study of Elafibranor in NASH Data Safety Monitoring Board (DSMB) recommended the continuation of  RESOLVE-IT without any modifications, based on the pre-planned review of safety data, including adverse events and laboratory data Positive recommendation consistent with previous observations sup...

Nicox and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize NCX 470 in the Chinese market

Press Release Nicox and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize NCX 470 in the Chinese market ............................................... Accesses

VALNEVA Initiates Phase 2 Clinical Development For Its Lyme Disease Vaccine Candidate

 Valneva Initiates Phase 2 Clinical Development For Its Lyme Disease Vaccine Candidate Saint-Herblain (France), December 17, 2018 - Valneva SE ("Valneva"), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, today announced the initiation of the Phase 2 Clinical Development for its leading, unique Lyme disease vaccine candida...

PRIME designation granted by European Medicines Agency for Roche's risdiplam for treatment of spinal muscular atrophy (SMA)

F. Hoffmann-La Roche Ltd / PRIME designation granted by European Medicines Agency for Roche's risdiplam for treatment of spinal muscular atrophy (SMA) . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Risdiplam has the potential to be the first oral medicine for the treatment of SMA Types 1, 2 and 3; a...

Sunday 16th December 2018

Arrayit Corporation Fulfills Clinical Instrumentation Contract with the United States Food and Drug Administration

Sunnyvale, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, reports fulfillment of a clinical instrumentation contract with the United States Food and Drug Administration (FDA), which involves an exacting series of contractual steps including receiving the solicitation, placing the bid, winning the award, receiving the purcha...

Friday 14th December 2018

The Finnish Competition and Consumer Authority has given the final approval for the transaction between Terveystalo and Attendo which is intended to be completed on 28 December 2018

Terveystalo Plc Stock exchange release 14 December 2018 at 13:00 EET Terveystalo signed an agreement on 17 May 2018 to acquire the Finnish healthcare operations of Attendo AB. The Finnish Competition and Consumer Authority (FCCA) has today 14 December 2018 given the final approval decision for the transaction. The Transaction is intended to be completed on 28 December 2018 provide...

Santhera Raises Gross Proceeds of CHF 23.5 Million and Secures Acquisition of Option to Vamorolone Sub-license

Santhera Pharmaceuticals Holding AG / Santhera Raises Gross Proceeds of CHF 23.5 Million and Secures Acquisition of Option to Vamorolone Sub-license . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Pratteln, Switzerland, December 14, 2018 - Santhera Pharmaceuticals Holding AG (SIX: SANN) has completed its ord...

Santhera Provides Update on the Share Placement

Santhera Pharmaceuticals Holding AG / Santhera Provides Update on the Share Placement . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Pratteln, Switzerland, December 14, 2018 - Santhera Pharmaceuticals Holding AG (SIX: SANN) provides an update on the accelerated bookbuilding. On December 12, 2018, Santhera Pha...

FIT Biotech Oy: FIT Biotech's financial calendar and Annual General Meeting in 2019

FIT Biotech Oy Company release 14.12.2018 at 09:00 AM EET FIT Biotech's financial calendar and Annual General Meeting in 2019During the year 2019, FIT Biotech Oy will publish the Financial Statement release 2018 and Half Year Financial Report 2019 as follows: Financial Statement Release 2018: Thursday 28 February 2019  Half Year Financial Report 1-6/2019: Thursday 5 S...

Thursday 13th December 2018

Immunicum AB (publ) Publishes the Outcome in the Share Issues and Raises SEK 351M

Press Release 13 December 2018 Immunicum AB (publ) Publishes the Outcome in the Share Issues and Raises SEK 351M NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL. Immunicum AB (publ) ("Immunicum"...

Ossur Hf : Financial calendar 2019

Announcement no. 71/201813 December 2018 Össur's financial calendar 2019 Interim Report Q4 2018 and Annual Report for 2018     5 February 2019 Annual General Meeting     7 March 2019 Interim Report Q1 2019    

Novartis receives European Commission approval for self-administration of Xolair® across all indications

Novartis International AG / Novartis receives European Commission approval for self-administration of Xolair® across all indications . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. The EC approval underscores the long-term safety and efficacy of Xolair demonstrated in clinical studies and by 13 years of re...

Pixium Vision awarded Galien Prize 2018 for research with PRIMA system

Pixium Vision awarded Galien Prize 2018 for research with PRIMA system for dry AMD Paris, France - December 13, 2018 - 7 AM CET - Pixium Vision (FR0011950641 - PIX), a bioelectronics company developing innovative bionic vision systems to enable patients who have lost their sight to lead more independent lives, announces today that it has been awarded the Prix Galien 2018 in the &qu...

Wednesday 12th December 2018

Ambu A/S: Articles of Association December 2018

  Attached Complete Articles of Association December 2018 Complete Articles of Association December 2018This announcement is distributed by West Corporation on behalf of West Corporation clients.The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.Source: Ambu A/S via Globenewswire

DBV Technologies Highlights Data Supporting Induction of Immunotolerance Through the Skin at Inflammatory Skin Disease Summit 2018

Montrouge, France, December 12, 2018 DBV Technologies Highlights Data Supporting Induction of Immunotolerance Through the Skin at Inflammatory Skin Disease Summit 2018 First-of-its-kind study evaluated immune profile of healthy human skin in different body sites Findings support application of epicutaneous immunotherapy (EPIT) to int

Santhera Announces Financial Results for the First Nine Months of 2018

Santhera Pharmaceuticals Holding AG / Santhera Announces Financial Results for the First Nine Months of 2018 . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Pratteln, Switzerland, December 12, 2018 - Santhera Pharmaceuticals (SIX: SANN) reports financial results for the nine months ended September 30, 2018, and...

Santhera Launches Placement of Shares through Accelerated Bookbuilding

Santhera Pharmaceuticals Holding AG / Santhera Launches Placement of Shares through Accelerated Bookbuilding . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Pratteln, Switzerland, December 12, 2018 - Santhera Pharmaceuticals Holding Ltd (SIX: SANN) announces the launch of an ordinary capital increase of up to 5...

Acacia Pharma Group plc: Acacia Pharma announces positive clinical results for APD403 in chemotherapy induced nausea & vomiting published in Supportive Care in Cancer

ACACIA PHARMA ANNOUNCES POSITIVE CLINICAL RESULTS FOR APD403 IN CHEMOTHERAPY INDUCED NAUSEA & VOMITING PUBLISHED IN SUPPORTIVE CARE IN CANCER Cambridge, UK and Indianapolis, US - 12 December 2018: Acacia Pharma Group plc ("Acacia Pharma", the "Company") (EURONEXT: ACPH) announces that data and analyses from its positive Phase 2 clinical trial of APD403 (int...

Tuesday 11th December 2018

Santhera's Extraordinary General Meeting Approves Capital Increase

Santhera Pharmaceuticals Holding AG / Santhera's Extraordinary General Meeting Approves Capital Increase . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Pratteln, Switzerland, December 11, 2018 - Santhera Pharmaceuticals (SIX: SANN) announces that a vast majority of shareholders approved the ordinary capit...

Neovacs and Centurion Pharma continue their collaboration in Lupus based on the results of the Phase IIb trial with IFNalpha Kinoid

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE Neovacs and Centurion Pharma continue their collaboration in Lupusbased on the results of the Phase IIb trial with IFNalpha Kinoid Paris and Boston, December 11th 2018 - 7:30 am CET - Neovacs (Euronext Growth Paris: ALNEV), leader in the field of active immune therapy for the treatment of autoimmune-diseas


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks